Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is obse...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: Ruella, Marco, Barrett, David M., Kenderian, Saad S., Shestova, Olga, Hofmann, Ted J., Perazzelli, Jessica, Klichinsky, Michael, Aikawa, Vania, Nazimuddin, Farzana, Kozlowski, Miroslaw, Scholler, John, Lacey, Simon F., Melenhorst, Jan J., Morrissette, Jennifer J.D., Christian, David A., Hunter, Christopher A., Kalos, Michael, Porter, David L., June, Carl H., Grupp, Stephan A., Gill, Saar
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096828/
https://ncbi.nlm.nih.gov/pubmed/27571406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87366
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares